Astellas stops development of H5N1 influenza vaccine ASP7373 and 7374

The cell-culture-based vaccine is directed against avian flu virus H5N1 and was jointly developed with IHI and UMN where Astellas had exclusive rights to sell the product in Japan.

Astellas news release January 12, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny